Brokerages expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.12). Aurinia Pharmaceuticals reported earnings per share of ($0.14) in the same quarter last year, which suggests a positive year over year growth rate of 7.1%. The business is expected to announce its next earnings report on Friday, August 4th.
On average, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($1.07) per share for the current fiscal year, with EPS estimates ranging from ($1.15) to ($0.89). For the next fiscal year, analysts expect that the firm will post earnings of ($0.61) per share, with EPS estimates ranging from ($0.74) to ($0.43). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 50.53% and a negative net margin of 48,278.23%. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million.
AUPH has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 20th. FBR & Co restated an “outperform” rating and set a $11.00 price objective (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, March 22nd. Cantor Fitzgerald initiated coverage on shares of Aurinia Pharmaceuticals in a report on Monday, April 10th. They set an “overweight” rating and a $14.00 price objective for the company. Finally, HC Wainwright decreased their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 18th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $9.64.
WARNING: “-$0.13 Earnings Per Share Expected for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) This Quarter” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://transcriptdaily.com/2017/08/13/0-13-earnings-per-share-expected-for-aurinia-pharmaceuticals-inc-nasdaqauph-this-quarter-updated-updated-updated.html.
Aurinia Pharmaceuticals (NASDAQ AUPH) traded down 8.99% during trading on Thursday, reaching $6.78. 4,572,399 shares of the company were exchanged. The firm has a 50-day moving average of $6.53 and a 200-day moving average of $5.36. Aurinia Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $10.54. The firm’s market cap is $564.58 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC boosted its position in Aurinia Pharmaceuticals by 18.2% in the first quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock valued at $35,294,000 after buying an additional 740,740 shares during the period. AWM Investment Company Inc. bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $2,202,000. Quantbot Technologies LP bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $275,000. Two Sigma Securities LLC bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $240,000. Finally, OTA Financial Group L.P. bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $1,291,000. Institutional investors own 29.25% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.